NO323646B1 - Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. - Google Patents

Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. Download PDF

Info

Publication number
NO323646B1
NO323646B1 NO19982794A NO982794A NO323646B1 NO 323646 B1 NO323646 B1 NO 323646B1 NO 19982794 A NO19982794 A NO 19982794A NO 982794 A NO982794 A NO 982794A NO 323646 B1 NO323646 B1 NO 323646B1
Authority
NO
Norway
Prior art keywords
aur
polypeptide
seq
acid sequence
amino acids
Prior art date
Application number
NO19982794A
Other languages
English (en)
Norwegian (no)
Other versions
NO982794D0 (no
NO982794L (no
Inventor
Gregory D Plowman
Kevin G Moissie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323646(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of NO982794D0 publication Critical patent/NO982794D0/no
Publication of NO982794L publication Critical patent/NO982794L/no
Publication of NO323646B1 publication Critical patent/NO323646B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
NO19982794A 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate. NO323646B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14
PCT/US1996/018859 WO1997022702A1 (en) 1995-12-18 1996-11-25 Diagnosis and treatment of aur-1 and/or aur-2 related disorders

Publications (3)

Publication Number Publication Date
NO982794D0 NO982794D0 (no) 1998-06-17
NO982794L NO982794L (no) 1998-08-18
NO323646B1 true NO323646B1 (no) 2007-06-18

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982794A NO323646B1 (no) 1995-12-18 1998-06-17 Nukleinsyremolekyl, nukleinsyreprobe, polypeptid, antistoff, hybridom, kit, anvendelse samt fremgangsmate.

Country Status (15)

Country Link
US (2) US5962312A (de)
EP (2) EP1655369A1 (de)
JP (1) JP3944241B2 (de)
KR (1) KR100459052B1 (de)
AT (1) ATE315654T1 (de)
AU (1) AU716330B2 (de)
CA (1) CA2239692C (de)
DE (1) DE69635740T2 (de)
DK (1) DK0868519T3 (de)
ES (1) ES2255715T3 (de)
IL (1) IL124728A (de)
NO (1) NO323646B1 (de)
NZ (1) NZ323795A (de)
PT (1) PT868519E (de)
WO (1) WO1997022702A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
ATE342971T1 (de) * 1997-08-15 2006-11-15 Univ Hiroshima Den zellzyklus regulierende proteine
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
CA2384291A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
AU2002322775A1 (en) * 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
EP1492871A2 (de) * 2002-03-28 2005-01-05 QLT Inc. Mit krebs assoziierte proteinkinasen und deren verwendung
FR2840905B1 (fr) 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
WO2004024063A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
SI1847539T1 (sl) 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
WO2004074518A1 (en) * 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
HUE050365T2 (hu) 2003-06-24 2022-09-28 Genomic Health Inc Rákkiújulás valószínûségének elõrejelzése
AU2004258085B2 (en) * 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
EP1694686A1 (de) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinaseinhibitoren
AU2004309396B2 (en) * 2003-12-23 2010-05-13 Genomic Health, Inc. Universal amplification of fragmented RNA
ES2636470T3 (es) * 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20050282208A1 (en) * 2004-06-18 2005-12-22 Cytokinetics, Inc. Cellular phenotype
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
KR20070113286A (ko) 2005-04-14 2007-11-28 에프. 호프만-라 로슈 아게 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080020412A1 (en) * 2006-01-03 2008-01-24 Romanowski Michael J Aurora expression constructs
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
JPH09501302A (ja) * 1993-04-07 1997-02-10 キャンサー リサーチ キャンペーン テクノロジー リミティド 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
WO1997022702A1 (en) 1997-06-26
AU716330B2 (en) 2000-02-24
EP1655369A1 (de) 2006-05-10
CA2239692A1 (en) 1997-06-26
PT868519E (pt) 2006-05-31
EP0868519B1 (de) 2006-01-11
DK0868519T3 (da) 2006-05-08
IL124728A0 (en) 1999-01-26
ES2255715T3 (es) 2006-07-01
NO982794D0 (no) 1998-06-17
CA2239692C (en) 2008-12-16
IL124728A (en) 2007-06-03
KR20000064437A (ko) 2000-11-06
JP3944241B2 (ja) 2007-07-11
US5972676A (en) 1999-10-26
EP0868519A1 (de) 1998-10-07
DE69635740D1 (de) 2006-04-06
KR100459052B1 (ko) 2005-01-15
JP2000502895A (ja) 2000-03-14
DE69635740T2 (de) 2006-09-14
ATE315654T1 (de) 2006-02-15
NZ323795A (en) 2000-01-28
NO982794L (no) 1998-08-18
US5962312A (en) 1999-10-05
AU1082697A (en) 1997-07-14

Similar Documents

Publication Publication Date Title
CA2239692C (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
EP1051500B1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
US7119174B2 (en) Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6495353B1 (en) Human orthologues of wart
US20080009610A1 (en) Diagnosis and treatment of PTP related disorders
CA2288221A1 (en) Diagnosis and treatment of phosphatase 0r kinase-related disorders
US6136581A (en) Kinase genes and uses
US6844177B2 (en) Diagnosis and treatment of PTP04 related disorders
WO1996037610A2 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
US5895813A (en) Diagnosis and treatment of TKA-1 related disorders
US6342593B1 (en) Diagnosis and treatment of ALP related disorders
US5922842A (en) Tyrosine kinase associated polypeptides
MXPA98004934A (en) Diagnosis and treatment of alterations related to aur-1 and / or au
WO1999027099A1 (en) Orf, a substrate for extracellular signal-regulated kinase, erk-6, and related methods

Legal Events

Date Code Title Description
MK1K Patent expired